Home » Stocks » Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. (ENTA)

Stock Price: $46.70 USD -0.35 (-0.74%)
Updated Aug 4, 2020 10:30 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 934.20M
Revenue (ttm) 175.87M
Net Income (ttm) 23.67M
Shares Out 20.00M
EPS (ttm) 1.13
PE Ratio 41.33
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $46.70
Previous Close $47.05
Change ($) -0.35
Change (%) -0.74%
Day's Open 47.17
Day's Range 46.62 - 47.19
Day's Volume 8,161
52-Week Range 38.40 - 76.16

More Stats

Market Cap 934.20M
Enterprise Value 587.43M
Earnings Date (est) Aug 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 20.00M
Float 16.10M
EPS (basic) 1.21
EPS (diluted) 1.13
FCF / Share 1.74
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.42%
FCF Yield 3.72%
Payout Ratio n/a
Shares Short 1.86M
Short Ratio 11.10
Short % of Float 11.60%
Beta 0.54
PE Ratio 41.33
Forward PE n/a
P/FCF Ratio 26.89
PS Ratio 5.31
PB Ratio 1.89
Revenue 175.87M
Operating Income 11.18M
Net Income 23.67M
Free Cash Flow 34.75M
Net Cash 346.77M
Net Cash / Share 17.33
Gross Margin 116.68%
Operating Margin 6.36%
Profit Margin 13.50%
FCF Margin 19.76%
ROA 1.43%
ROE 5.13%
ROIC 1.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 2
Overweight 1
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$68.33*
(46.32% upside)
Low
47.0
Current: $46.70
High
119.0
Target: 68.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue20520710388.2716147.7432.0541.7141.8822.76
Revenue Growth-0.69%100.97%16.48%-45.13%236.98%48.94%-23.15%-0.42%83.99%-
Gross Profit20520710388.2716147.7432.0541.7141.8822.76
Operating Income36.7488.3324.6130.8412418.999.0321.2925.306.94
Net Income46.3871.9617.7121.6778.9934.449.6321.4023.317.90
Shares Outstanding19.5819.2619.0718.9318.6718.369.791.091.121.13
Earnings Per Share2.213.480.911.134.091.80-0.671.131.320.18
EPS Growth-36.49%282.42%-19.47%-72.37%127.22%---14.39%633.33%-
Operating Cash Flow71.4229.2252.6535.8176.6720.1810.6522.6224.02-10.18
Capital Expenditures-5.42-2.98-2.51-4.74-2.34-1.03-0.61-0.19-0.44-0.04
Free Cash Flow66.0026.2450.1531.0774.3419.1510.0522.4423.58-10.21
Cash & Equivalents33630922421114691.2010244.2024.910.00
Net Cash / Debt33630922421114691.2010244.2024.910.00
Assets49041432728124615511752.1626.10-
Liabilities27.3420.5524.9611.349.866.766.518.234.14-
Book Value462394302270236149110-115-132-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Enanta Pharmaceuticals, Inc.
Country United States
Employees 132
CEO Jay R. Luly

Stock Information

Ticker Symbol ENTA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ENTA
IPO Date March 21, 2013

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.